DE69529173D1 - Heterozyklische bizykeln zur behandlung von impotenz - Google Patents
Heterozyklische bizykeln zur behandlung von impotenzInfo
- Publication number
- DE69529173D1 DE69529173D1 DE69529173T DE69529173T DE69529173D1 DE 69529173 D1 DE69529173 D1 DE 69529173D1 DE 69529173 T DE69529173 T DE 69529173T DE 69529173 T DE69529173 T DE 69529173T DE 69529173 D1 DE69529173 D1 DE 69529173D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- ones
- impotence
- pharmaceutical composition
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9423911A GB9423911D0 (en) | 1994-11-26 | 1994-11-26 | Therapeutic agents |
PCT/EP1995/004065 WO1996016657A1 (en) | 1994-11-26 | 1995-10-16 | Bicyclic heterocyclic compounds for the treatment of impotence |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69529173D1 true DE69529173D1 (de) | 2003-01-23 |
DE69529173T2 DE69529173T2 (de) | 2003-05-22 |
Family
ID=10765032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69529173T Expired - Fee Related DE69529173T2 (de) | 1994-11-26 | 1995-10-16 | Heterozyklische bizykeln zur behandlung von impotenz |
Country Status (12)
Country | Link |
---|---|
US (2) | US6100270A (de) |
EP (1) | EP0793498B1 (de) |
JP (2) | JPH09512835A (de) |
AT (1) | ATE229335T1 (de) |
CA (1) | CA2203389C (de) |
DE (1) | DE69529173T2 (de) |
DK (1) | DK0793498T3 (de) |
ES (1) | ES2187578T3 (de) |
GB (1) | GB9423911D0 (de) |
MX (1) | MX9703840A (de) |
PT (1) | PT793498E (de) |
WO (1) | WO1996016657A1 (de) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060222647A1 (en) * | 1993-05-27 | 2006-10-05 | Beavo Joseph A | Methods and compositions for modulating the activity of PDE5 |
NZ338075A (en) | 1997-04-25 | 2000-10-27 | Pfizer Ltd | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PED5) for the treatment of sexual dysfunction |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
CU23063A3 (es) * | 1997-11-12 | 2005-07-19 | Bayer Ag | Imidazotriazinonas 2-fenil sustituidas como inhibidores de fosfodiesterasas |
TW542719B (en) * | 1998-02-23 | 2003-07-21 | Pfizer Res & Dev | Method of treating impotence due to spinal cord injury |
TR200003039T2 (tr) * | 1998-04-20 | 2001-01-22 | Pfizer Inc. | Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri |
WO2000014088A1 (en) * | 1998-09-04 | 2000-03-16 | Ortho-Mcneil Pharmaceutical, Inc. | 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction |
GB9823102D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
GB9823101D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
GB9823103D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
KR100353014B1 (ko) * | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
CA2362918A1 (en) * | 1999-03-08 | 2000-09-14 | Elizabeth Stoner | Methods and compositions for treating erectile dysfunction |
NO20002097L (no) * | 1999-04-30 | 2001-10-26 | Lilly Icos Llc | Fremstillingsgjenstander |
AU5925500A (en) * | 1999-07-09 | 2001-01-30 | Picower Institute For Medical Research, The | Pyrazolopyrimidinone derivatives conjugated to thiophene moieties or benzo [fused] 5-membered heterocycles for erectile dysfunction |
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
DZ3218A1 (fr) * | 1999-10-11 | 2001-04-19 | Pfizer | Pyrimidine-7-ones 5-(2-substitutees-5-heterocyclylsulphonylpyride-3-yl)-dihydropyrazolo[4,3-d] servant d'inhibiteurs de la phosphodiesterase |
GB9924020D0 (en) * | 1999-10-11 | 1999-12-15 | Pfizer Ltd | Pharmaceutically active compounds |
UA74826C2 (en) | 2000-05-17 | 2006-02-15 | Ortho Mcneil Pharm Inc | ?-carboline derivatives as phosphodiesterase inhibitors |
DE10031584A1 (de) | 2000-06-29 | 2002-01-10 | Merck Patent Gmbh | 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine |
US6953774B2 (en) * | 2000-08-11 | 2005-10-11 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
AU8444401A (en) | 2000-09-06 | 2002-03-22 | Tanabe Seiyaku Co | Preparations for oral administration |
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
WO2002030470A1 (en) | 2000-10-13 | 2002-04-18 | Johns Hopkins University | Methods and compositions for nucleic acid delivery |
DE10058662A1 (de) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Pyrazolo[4,3-d]pyrimidinen |
AU2002230217B2 (en) | 2001-02-15 | 2005-02-17 | Tanabe Seiyaku Co., Ltd. | Tablets quickly disintegrated in oral cavity |
IL158738A0 (en) * | 2001-05-09 | 2004-05-12 | Bayer Healthcare Ag | Novel use of 2-phenyl-substituted imidazotriazinones |
ES2302835T3 (es) * | 2001-08-28 | 2008-08-01 | Schering Corporation | Inhibidores de fosfodiesterasa v policiclicos de guanina. |
JP2005509038A (ja) * | 2001-11-09 | 2005-04-07 | シェーリング コーポレイション | 多環式グアニン誘導体ホスホジエステラーゼv阻害剤 |
BRPI0207215B8 (pt) * | 2001-12-13 | 2022-11-01 | Daiichi Suntory Biomedical Res Limited | Derivados de pirazolopirimidinona tendo ação de inibição de pde7 |
WO2003053923A2 (en) | 2001-12-20 | 2003-07-03 | Applied Research Systems Ars Holding N.V. | Pyrrolidine derivatives as prostaglandin modulators |
DE10232113A1 (de) | 2002-07-16 | 2004-01-29 | Bayer Ag | Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel |
GEP20084329B (en) | 2003-04-29 | 2008-03-25 | Pfizer Ltd | 5,7-diaminopyrazolo [4,3-d] pyrimidines useful in the treatment of hypertension |
CN100374441C (zh) | 2003-06-06 | 2008-03-12 | 天津倍方科技发展有限公司 | 二氢吡咯[2,3-d]嘧啶-4-酮衍生物,其制备方法及其制药用途 |
EP2526958B1 (de) * | 2003-06-13 | 2017-10-18 | Ironwood Pharmaceuticals, Inc. | Verfahren und Zusammensetzungen zur Behandlung von Magen-Darm-Störungen |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
CA2562251C (en) | 2004-04-07 | 2009-04-28 | Pfizer Inc. | Pyrazolo'4,3-d pyrimidines |
DE102004023069A1 (de) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
DE102005009240A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften |
EP2275095A3 (de) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
JP2009509984A (ja) * | 2005-09-29 | 2009-03-12 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 泌尿器系障害の処置用のpde阻害剤およびそれらの組合せ |
EP2377530A3 (de) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation von Neurogenese durch PDE-Hemmung |
EP2314289A1 (de) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2007110868A2 (en) | 2006-03-28 | 2007-10-04 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
JP2010505811A (ja) | 2006-10-04 | 2010-02-25 | ファイザー・プロダクツ・インク | カルシウム受容体アンタゴニストとしてのピリド[4,3−d]ピリミジン−4(3H)−オン誘導体 |
JP2010532319A (ja) * | 2007-06-13 | 2010-10-07 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 聴覚障害の処置用のpde阻害剤 |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US20100261737A1 (en) * | 2009-04-10 | 2010-10-14 | Medtronic Vascular, Inc. | Method of Treating Erectile Dysfunction |
EP2697206B1 (de) | 2011-04-10 | 2019-04-03 | Atir Holding S.A. | Heterocyclische verbindungen und ihre verwendung bei der behandlung von sexuellen funktionsstörungen |
EP2804603A1 (de) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Betazellen-replikation für promoterverbindungen und verwendungsverfahren dafür |
WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
EP3562828A1 (de) | 2016-12-28 | 2019-11-06 | Dart NeuroScience LLC | Substituierte pyrazolopyrimidinonverbindungen als pde2-inhibitoren |
MX2020005447A (es) | 2017-11-27 | 2020-12-03 | Dart Neuroscience Llc | Compuestos de furanopirimidina sustituida como inhibidores de pde1. |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2547501A1 (fr) * | 1983-06-15 | 1984-12-21 | Opochimiotherapie Lab | Excipient effervescent, sans alcalino-terreux, contenant des composes carbonates de l'arginine et un acide, et comprimes effervescents correspondants |
IT1217190B (it) | 1988-04-22 | 1990-03-14 | Recordati Chem Pharm | Composti utili per il trattamento e diagnosi di disfunzioni frettili |
JPH0344324A (ja) | 1989-07-13 | 1991-02-26 | Kazuoki Tsuchiya | 性機能賦活剤 |
JP3044324B2 (ja) | 1990-02-15 | 2000-05-22 | サカタインクス株式会社 | すべり止めニス及びそれを用いたすべり止め加工方法並びにすべり止め加工を施した段ボールの製造方法 |
GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9114760D0 (en) * | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
GB9119704D0 (en) * | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
CA2079374C (en) * | 1991-09-30 | 2003-08-05 | Merck Frosst Canada Incorporated | (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
GB9121028D0 (en) * | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
GB9126260D0 (en) * | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
GB9213623D0 (en) * | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
GB9218322D0 (en) * | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
GB9312210D0 (en) * | 1993-06-14 | 1993-07-28 | Smithkline Beecham Plc | Chemical compounds |
-
1994
- 1994-11-26 GB GB9423911A patent/GB9423911D0/en active Pending
-
1995
- 1995-10-16 DE DE69529173T patent/DE69529173T2/de not_active Expired - Fee Related
- 1995-10-16 EP EP95935453A patent/EP0793498B1/de not_active Expired - Lifetime
- 1995-10-16 JP JP8518108A patent/JPH09512835A/ja active Pending
- 1995-10-16 ES ES95935453T patent/ES2187578T3/es not_active Expired - Lifetime
- 1995-10-16 MX MX9703840A patent/MX9703840A/es not_active IP Right Cessation
- 1995-10-16 AT AT95935453T patent/ATE229335T1/de not_active IP Right Cessation
- 1995-10-16 US US08/836,671 patent/US6100270A/en not_active Expired - Lifetime
- 1995-10-16 PT PT95935453T patent/PT793498E/pt unknown
- 1995-10-16 CA CA002203389A patent/CA2203389C/en not_active Expired - Fee Related
- 1995-10-16 WO PCT/EP1995/004065 patent/WO1996016657A1/en active IP Right Grant
- 1995-10-16 DK DK95935453T patent/DK0793498T3/da active
-
2000
- 2000-04-03 US US09/542,489 patent/US6534511B1/en not_active Expired - Lifetime
- 2000-05-02 JP JP2000133197A patent/JP2001048787A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US6100270A (en) | 2000-08-08 |
JPH09512835A (ja) | 1997-12-22 |
JP2001048787A (ja) | 2001-02-20 |
EP0793498B1 (de) | 2002-12-11 |
CA2203389C (en) | 2002-12-17 |
MX9703840A (es) | 1997-08-30 |
DE69529173T2 (de) | 2003-05-22 |
ES2187578T3 (es) | 2003-06-16 |
WO1996016657A1 (en) | 1996-06-06 |
GB9423911D0 (en) | 1995-01-11 |
ATE229335T1 (de) | 2002-12-15 |
DK0793498T3 (da) | 2003-01-13 |
CA2203389A1 (en) | 1996-06-06 |
EP0793498A1 (de) | 1997-09-10 |
US6534511B1 (en) | 2003-03-18 |
PT793498E (pt) | 2003-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69529173D1 (de) | Heterozyklische bizykeln zur behandlung von impotenz | |
YU73991A (sh) | POSTUPAK ZA DOBIJANJE 2-METIL-10-(4-METIL-1-PIPERAZINIL)-4H- TIENO 2,3-b 1,5 BENZODIAZEPINA | |
DE69635959D1 (de) | Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme | |
ATE297208T1 (de) | Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit | |
BRPI0009719B8 (pt) | processo de tratamento | |
MY106528A (en) | Method of treating impotence. | |
FI905674A0 (fi) | Menetelmä valmistaa farmaseuttisesti käyttökelpoisia 5,11-dihydro-6H-dipyrido/3,2-b:2',3'-e//1,4/diatsepin-6-oneja ja -tioneja | |
EE200100388A (et) | Püridasino [4,5-b] indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite düsfunktsioneerimisega seotud haiguste raviks | |
RU94002133A (ru) | 6-хлор-5-фтор-3-(2-теноил)-2-оксиндол-1-карбоксамид как аналгезирующее и противовоспалительное средство | |
HUP9902094A2 (hu) | PGE-1-tartalmú liofilizált liposzómák erekciós zavar kezelésében való alkalmazásra | |
EP0362847A3 (de) | Verwendung von Etoperidon zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von männlicher Impotenz | |
DE2964557D1 (en) | 9,10-dihydro-4h-benzo(4,5)cyclohepta(1,2-b)thiophen-4,9 imines, process for their preparation and pharmaceutical compositions containing them | |
EP0408525A3 (en) | Use in therapy of 10-amino-5,6-dihydro-11h-dibenzo(b,e)azepine-6,11-dione and derivatives as drugs for use in the treatment of urinary incontinence | |
ITMI941939A0 (it) | Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids | |
TW333453B (en) | Pharmaceutical composition comprising toremifene for use in the treatment of autoimmune diseases | |
IT8922778A0 (it) | Dispositivo per l'applicazione della ionoforesi nella cura dell'impotenza maschile, in particolare per la cura dell'impotenza erettile | |
GEP20043348B (en) | Pyrazolopyrimidinone Antianginal Agents | |
MX9706825A (es) | El uso farmacologico de ciertos derivados de cistina. | |
PT84275A (en) | Process for the preparation of tetracyclic quinazolinones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: PFIZER IRELAND PHARMACEUTICALS (A PARTNERSHIP BETW |
|
8339 | Ceased/non-payment of the annual fee |